Ferozsons Laboratories Limited

Ferozsons Laboratories Limited has entered into a non-exclusive voluntary license agreement with #GileadSciences Ireland UC for the manufacture and sale of licensed generic #lenacapavir in resource-constrained, high burden and resource-limited countries in the developing world. #Ferozsons is one of six global partners to have successfully signed a voluntary license agreement with #Gilead to produce high-quality generic of #lenacapavir. Lenacapavir is approved by US #FDA for infection caused by the #humanimmunodeficiencyvirus (HIV) for heavily treatment-experienced patients (“HTE”), and is being investigated for use in #HIV prevention. The agreement covers lenacapavir for HIV prevention (pending approval), in addition to the approved indication of HIV treatment in heavily treatment-experienced (HTE) adults with multi-drug resistant HIV. Under this non-exclusive license, Ferozsons or its affiliates can manufacture and sell, subject to required regulatory approvals, its licensed generic of Gilead proprietary compound Lenacapavir in 120 (one hundred twenty) primarily low and lower- middle income countries. Under the licensing agreement, the company has a right to receive a technology transfer of the Gilead manufacturing process for lenacapavir to enable it to scale up production. Lenacapavir is available in two dosage forms: (a) an injectable drug product in a vial kit configuration containing 309 mg/mL Lenacapavir, or, (b) an oral tablet drug product containing 300mg of Lenacapavir. The injectable drug product will be manufactured at BF Biosciences (a subsidiary Of Ferozsons Group), while the oral variant will be manufactured at Ferozsons’ oral solid dosage (OSD) facility. #Ferozsons #PuttingPatientsFirst #PeopleTrustUs #Collaboration #Partnership #healthsolutions https://lnkd.in/g6jYTTse

The Pakistan Stock Exchange (PSX) held a gong ceremony to celebrate the listing of BF Biosciences Limited (BFBIO). BFBIO is a pharmaceutical joint venture between… Read More: https://lnkd.in/d_VaZQWe

Pre-Gap Assessment Completed for PICS Audit by Simmon Hoffman at BF Biosciences, marking a significant step towards our goal of achieving another milestone in compliance. This assessment brings us closer to our PICS Audit, reinforcing our commitment to maintaining the highest standards in pharmaceutical manufacturing. A big thanks to everyone involved for their dedication and teamwork.  #PICS #Compliance #Teamwork

Early Detect, Early Protect! Be aware of these risks of developing breast cancer #Breastcancerawareness #Peopletrustus #Becausewecare #Puttingpatientsfirst

Early Detect, Early Protect! Be proud of the scars you carry. #Breastcancerawareness #Peopletrustus #Becausewecare #Puttingpatientsfirst

Early Detect, Early Protect! Here are some ways to prevent breast cancer #Breastcancerawareness #Peopletrustus #Becausewecare #Puttingpatientsfirst

Early Detect, Early Protect! Though not common, men are also at risk of breast cancer #Breastcancerawareness #Peopletrustus #Becausewecare #Puttingpatientsfirst

Early Detect, Early Protect! In this month lets support patients, survivors, and their families. Together, we can make a difference #Breastcancerawareness #Peopletrustus #Becausewecare #Puttingpatientsfirst

Early Detect, Early Protect! Breast cancer is also one of the leading causes of cancer deaths among women! #Breastcancerawareness #Peopletrustus #Becausewecare #Puttingpatientsfirst

Early Detect, Early Protect! Early detection is a key to success in the fight against breast cancer. #Breastcancerawareness #Peopletrustus #Becausewecare #Puttingpatientsfirst